Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HBAI20 hepatitis B vaccine in hepatitis B vaccine non-responders
NL-OMON47410Phase 2Active, not recruiting
- Sponsor
- CyTuVax
- Start
- Mar 2017
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of HBAI20 in hepatitis B (HBV), sponsored by CyTuVax. Primary endpoints: Immunogenicity efficacy and Seroprotection. Started Mar 2017; status: active, not recruiting.
02
Drugs
HBAI20
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NL-OMON47410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47410.